Lilly Settles Cialis Generic Patent Suit, Cuts Exclusivity

Law360, New York (July 13, 2017, 10:22 PM EDT) -- Eli Lilly and Company reached a settlement in Virginia federal court with generic drug companies accused of infringing its unit-dose patent for its sexual dysfunction treatment Cialis, maintaining its market exclusivity until at least next fall, the company announced Wednesday.

The settlement brings to a close Lilly’s consolidated suits against five generic drug producers alleging infringement of a patent describing the particular unit dosage of certain enzyme inhibitors that can effectively treat sexual dysfunction. The patent was slated to expire on April 26, 2020, but the...
To view the full article, register now.